Provention Bio appointed Dr. Jan Hillson as senior vice president of clinical development, according to a Wednesday announcement. Hillson bolsters the Red Bank-based pharmaceutical company’s clinical development leadership group with significant experience in all phases of clinical development across various autoimmune disorders.
“Jan will be making an immediate impact as our medical lead for the PREVAIL-2 study, where she brings significant experience in the treatment of systemic lupus erythematosus patients,” stated Dr. Eleanor Ramos, chief medical officer, Provention Bio. “Given Jan’s immune-focused drug development track record of successfully advancing novel treatments to patients, she also further broadens our capabilities to identify additional product candidates to intercept autoimmune diseases with significant unmet medical need.”
Hillson brings over two decades of experience in academic research, patient care, teaching and directing strategy and operations of clinical research and translational medicine programs. She most recently served as senior vice president, clinical development, at Alpine Immune Sciences. She also served as senior vice president of clinical and translational research at ChemoCentryx.
Hillson additionally held roles of increasing responsibility at Momenta Pharmaceuticals, ZymoGenetics, Bristol-Myers Squibb and Xcyte Therapies.
